Healio Coverage

November 23, 2020
1 min read

Top in cardiology: More AHA Scientific Sessions highlights


Healio Coverage

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Healio’s live coverage of the virtual American Heart Association Scientific Sessions dominated the top stories in cardiology for the second week in a row.

Top stories included trial results that showed a high-dose influenza vaccine failed to reduce cardiovascular events in a high-risk cohort and a report on several studies that indicated cannabis users are at higher risk for acute MI.

Source: Adobe Stock

Read these and more top stories in cardiology below:

INVESTED: High-dose influenza vaccine fails to reduce death, CV events in high-risk cohort

Injection of a high-dose influenza vaccine did not affect all-cause death, cardiac or pulmonary hospitalization compared with a lower dose in patients with prior MI or heart failure hospitalization, according to findings from the INVESTED trial. Read more.

Cannabis use may confer increased admission for acute MI, worse outcomes in PCI

Cannabis use in the U.S. is rising, and although users are typically younger, their risk for acute MI is elevated, and after percutaneous coronary intervention, cannabis users may be at increased risk for bleeding and stroke compared with nonusers, researchers reported. Read more.

STRENGTH: No CV benefit with omega-3 carboxylic acid

Administration of high-dose omega-3 carboxylic acid compared with corn oil placebo did not reduce incidence of major adverse CV events among statin-treated adults with elevated triglycerides at high CV risk. Read more.

‘Nocebo effect’ may explain many cases of statin intolerance: SAMSON

Patients who developed symptoms within 2 weeks of statin initiation reported similar adverse effects while on placebo, suggesting a large proportion of burden owed to the nocebo effect, according to findings from the SAMSON trial. Read more.

COVID-19 CVD registry highlights racial/ethnic disparities, risk in obesity

CVD complications in patients with COVID-19 are less common than were believed, but COVID-19 complications disproportionately affect patients with obesity and Black and Hispanic individuals, according to new registry data. Read more.